MA
MAXHEALTH
MAXHEALTH Max Healthcare Institute Q1 FY26 results (Apr–Jun 2025) and concall
Management summary
- Max Healthcare delivered strong Q1 FY26 performance with robust growth metrics, extending its growth streak to 19 consecutive quarters.
- The results demonstrate successful execution of acquisition integration and expansion strategy.
Source: Inve concall analysis and management guidance record.
What they filed
| Line item | Q3 FY25 | Q4 FY25 | Q1 FY26 |
|---|---|---|---|
| Revenue | 1,868 | 1,910 | 2,028 |
| EBITDA | 499 | 512 | 523 |
| Net profit | 239 | 319 | 308 |
How to read this
₹ crore, as filed. The percentage beside a figure is the change against the same quarter a year earlier — never the quarter before, which would make every seasonal business look like it collapses and booms each year.
Unlock risks & concerns, Q2 FY26 watchlist, and full call analysis
You’re reading a preview. Opening the full call uses 1 concall credit and unlocks:
- Risks, concerns & management red flags
- Watchlist triggers for Q2 FY26
- Full section-by-section call narrative
Sign in to use your monthly call allowance.
Inve summary of a publicly available earnings call transcript; see how call summaries are prepared and our regulatory disclaimer. · Share on WhatsApp · Scorecard image





